How We Do It

Coordination of Care in Breast Cancer Survivors: An Overview

The number of breast cancer survivors in the United States is increasing. With longer survival, there has been an increase in the complexity and duration of posttreatment care. Multidisciplinary care teams are needed to participate across the broad spectrum of issues that breast cancer survivors face. In this setting, the need for well-established patterns of communication between care providers is increasingly apparent. We have created a multidisciplinary approach to the management of breast cancer survivors to improve communication and education between providers and patients. This approach could be extended to the care and management of survivors of other types of cancer.



 

The Journal of Supportive Oncology
Volume 9, Issue 6, November-December 2011, Pages 210-215
doi:10.1016/j.suponc.2011.06.008 | How to Cite or Link Using DOI
Permissions & Reprints

How We Do It

Coordination of Care in Breast Cancer Survivors: An Overview
Kimberly S. Peairs MD
,
, Antonio C. Wolff MD, FACP, Sharon J. Olsen PhD, Elissa T. Bantug MHS, Lillie Shockney RN, BS, MAS, Melinda E. Kantsiper MD, Elisabeth Carrino-Tamasi MSW, LGSW, Claire F. Snyder PhD
[Author vitae]
Received 3 March 2011; Accepted 18 June 2011. Available online 3 November 2011.

TO READ THE ENTIRE ARTICLE, CLICK ON THE ADJACENT LINK TO THE PDF FILE

Abstract

The number of breast cancer survivors in the United States is increasing. With longer survival, there has been an increase in the complexity and duration of posttreatment care. Multidisciplinary care teams are needed to participate across the broad spectrum of issues that breast cancer survivors face. In this setting, the need for well-established patterns of communication between care providers is increasingly apparent. We have created a multidisciplinary approach to the management of breast cancer survivors to improve communication and education between providers and patients. This approach could be extended to the care and management of survivors of other types of cancer.

Case

A 65-year-old woman with stage II breast cancer, mild hypertension, and obesity recently completed treatment for her estrogen/progesterone receptor–positive, HER 2–negative breast cancer. She was treated with lumpectomy, radiation therapy, and adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by paclitaxel. She remains on an aromatase inhibitor and is experiencing arthralgias, numbness in her extremities, fatigue, and apprehension about cancer recurrence. She has not seen her primary care physician since the start of her cancer treatment but is concerned that her “heart” and bones may be affected by her therapy.

Vitae

Dr. Peairs is from the Johns Hopkins School of Medicine, Baltimore, Maryland.

Dr. Wolff is from the Johns Hopkins School of Medicine, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

Dr. Olsenis from the Johns Hopkins School of Nursing, Baltimore, Maryland.

Dr. Bantugis from the Johns Hopkins School of Medicine, Baltimore, Maryland.

Dr. Shockney is from the Johns Hopkins School of Medicine, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

Dr. Kantsiper is from the Johns Hopkins School of Medicine, Baltimore, Maryland.

Dr. Carrino-Tamasi is from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

Dr. Snyder is from the Johns Hopkins School of Medicine, Baltimore, Maryland.

The Journal of Supportive Oncology
Volume 9, Issue 6, November-December 2011, Pages 210-215

Recommended Reading

Letter - Acneiform Rash as a Reaction to Radiotherapy in a Breast Cancer Patient
Breast Cancer ICYMI
Study: Flaxseed Bars Not Effective in Reducing Hot Flashes
Breast Cancer ICYMI
Screen Breast Cancer Patients for Depression
Breast Cancer ICYMI
New Nomograms Predict Lymphedema After Axillary Lymph Node Dissection
Breast Cancer ICYMI
FDA Panel: Update Bisphosphonate Labeling
Breast Cancer ICYMI
Venlafaxine, Clonidine Top Placebo for Breast Cancer Hot Flashes
Breast Cancer ICYMI
Denosumab Approved for Bone Loss From Hormone Ablation Therapy
Breast Cancer ICYMI
Commentary: Depression Stymies Care in Latina Breast Cancer Survivors
Breast Cancer ICYMI
Taxane-Induced Neuropathy Gives No Clue to Breast Cancer Outcomes
Breast Cancer ICYMI
Radiopharmaceuticals: When and How to Use Them to Treat Metastatic Bone Pain
Breast Cancer ICYMI